NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Intellia Therapeutics, Inc. NTLA lost 21.6% in a week as investors were disappointed with the company’s plans for portfolio ...

The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.

Intellia Therapeutics Inc (NTLA) stock saw a modest uptick, ending the day at $9.5 which represents a slight increase of $0.08 or 0.85% from the prior close of $9.42. The stock opened at $9.48 and ...

Wedbush reaffirmed their neutral rating on shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) in a report published ...

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.

Intellia Therapeutics Inc (NTLA) stock saw a decline, ending the day at $9.42 which represents a decrease of $-0.29 or -2.99% from the prior close of $9.71. The stock opened at $9.76 and touched a low ...

Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for ...

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its price target dropped by equities research analysts at BMO Capital Markets from $70.00 to $50.00 in a research report issued to clients and ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Intellia ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Technical analysis for Intellia Therapeutics Inc. NTLA including support levels resistance levels and stop losses for NTLA ...